Cardiol Therapeutics Inc. (CRDL) - Pangali EV/EBITDA

The EV/EBITDA price chart for Cardiol Therapeutics (CRDL) stands at 0.00. The business focuses on developing anti-inflammatory cardiac treatments, where fixed testing costs transition into high margins during mass production. Current financial stability is limited by the trial stage of cannabidiol-based drugs; however, shareholder confidence is bolstered by strong capital and the proficient leadership of David Elsly.

Cardiol Therapeutics (CRDL) fully outsources its production and research to external contractors, which eliminates the need for its own capital assets. Under these conditions, the EV/EBITDA valuation multiple for capital-intensive businesses relates the total enterprise value of the company to its operating profit before depreciation and taxes, allowing investors to identify market undervaluation of the asset or the risk of overpayment during periods of volatility.